DR3, ED, Blocking Peptide (Death Receptor3), Purified

Peptide corresponding to amino acids 59 to 77 in extracellular domain (ED) of human DR3 precusor1,2., Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand of the TNF family through their death domain containing receptors, TNFR1 and Fas. A novel cell death receptor was recently identified by several groups independently and designated DR3, Wsl-1, Apo-3, TRAMP and LARD1-5. The ligand for this novel death receptor has been defined as TWEAK, also termed Apo3L. DR3 is highly expressed in the tissues enriched in lymphocytes including PBL, thymus and spleen. Like TNFR1, DR3 induces apoptosis and NF-kB activation. Location: aa 59-77 of human DR3, Applications: Suitable for use in Antibody Blocking. Other applications not tested. Recommended Dilutions: Antibody Blocking: Incubate with equal volume of antibody (D9300-20) for 30mins at 37ºC., Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.